[go: up one dir, main page]

MX2016010877A - Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos. - Google Patents

Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos.

Info

Publication number
MX2016010877A
MX2016010877A MX2016010877A MX2016010877A MX2016010877A MX 2016010877 A MX2016010877 A MX 2016010877A MX 2016010877 A MX2016010877 A MX 2016010877A MX 2016010877 A MX2016010877 A MX 2016010877A MX 2016010877 A MX2016010877 A MX 2016010877A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
antimitotic
amides
proliferative disorders
Prior art date
Application number
MX2016010877A
Other languages
English (en)
Other versions
MX390530B (es
Inventor
Siddiqui-Jain Adam
Original Assignee
Frost Biologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frost Biologic Inc filed Critical Frost Biologic Inc
Publication of MX2016010877A publication Critical patent/MX2016010877A/es
Publication of MX390530B publication Critical patent/MX390530B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se describen nuevas heteroaril amidas antimitóticas y sales farmacéuticamente aceptables de la Formula I en donde Ar, R5, R6, R8, R9, R11, X1, y X2 son como se definen en la presente, como compuestos para el tratamiento y la prevención del cáncer y desordenes y enfermedades proliferativas. (Ver Fórmula).
MX2016010877A 2014-02-21 2015-02-20 Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos. MX390530B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461942956P 2014-02-21 2014-02-21
PCT/US2015/016928 WO2015127284A2 (en) 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders

Publications (2)

Publication Number Publication Date
MX2016010877A true MX2016010877A (es) 2017-05-04
MX390530B MX390530B (es) 2025-03-20

Family

ID=52684675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010877A MX390530B (es) 2014-02-21 2015-02-20 Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos.

Country Status (15)

Country Link
US (4) US10016398B2 (es)
EP (1) EP3107909B1 (es)
JP (1) JP6506313B2 (es)
KR (1) KR102420508B1 (es)
CN (2) CN114634483B (es)
AU (1) AU2015218775C1 (es)
BR (1) BR112016019161B1 (es)
CA (1) CA2940237C (es)
ES (1) ES2893374T3 (es)
IL (1) IL247293B (es)
MX (1) MX390530B (es)
RU (1) RU2713179C2 (es)
SG (2) SG10202000590SA (es)
WO (1) WO2015127284A2 (es)
ZA (1) ZA201606471B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420622B1 (en) 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
JP6506313B2 (ja) * 2014-02-21 2019-04-24 フロスト バイオロジック，インコーポレーテッド 癌及び増殖性疾患の治療のための抗有糸分裂性アミド
CN106727583A (zh) * 2016-12-12 2017-05-31 范旭升 一种治疗舒张性心衰的药物组合物
US11377436B2 (en) * 2017-07-12 2022-07-05 The Brigham And Women's Hospital, Inc. EAAT2 enhancing molecules
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
WO2025248483A1 (ko) * 2024-05-30 2025-12-04 삼진제약주식회사 Nr2f6 억제제 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
BR0111280A (pt) * 2000-06-05 2003-06-10 Dong A Pharm Co Ltd Novos derivados de oxazolidinona e um processo para a preparação dos mesmos
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
MXPA06015106A (es) * 2004-06-30 2007-02-08 Novartis Ag Metodo para aumentar la susceptibilidad de los inhibidores de la peptidil-desformilasa mediante la utilizacion de inhibidores de la bomba de eflujo.
US20090156646A1 (en) * 2005-08-11 2009-06-18 Takeda Pharmaceutical Company Limited Pyridylphenol compound and use thereof
PL1984338T3 (pl) * 2006-01-31 2013-06-28 Synta Pharmaceuticals Corp Związki pirydylofenylowe do zastosowań związanych z zapaleniami i odpornością
JP2010510191A (ja) 2006-11-17 2010-04-02 スミスクライン ビーチャム コーポレーション 抗ウイルス剤としての２−カルボキシチオフェン誘導体
DE602008004650D1 (de) * 2007-04-12 2011-03-03 Hoffmann La Roche Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase
US20110118281A9 (en) * 2008-10-01 2011-05-19 Gary Bohnert Compounds for inflammation and immune-related uses
WO2010100475A1 (en) * 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
ES2528485T3 (es) * 2009-09-11 2015-02-10 Amgen, Inc N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina para su uso en el tratamiento del cáncer resistente a agentes antimitóticos
PT2563776T (pt) * 2010-04-27 2016-09-19 Calcimedica Inc Compostos que modulam o cálcio intracelular
US20130063385A1 (en) * 2010-05-14 2013-03-14 Sharp Kabushiki Kaisha Portable information terminal and method for controlling same
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
JP2014503000A (ja) * 2011-01-21 2014-02-06 アッヴィ・インコーポレイテッド キナーゼのピコリンアミド阻害剤
US8748432B2 (en) * 2011-02-10 2014-06-10 Syngenta Participations Ag Microbiocidal pyrazole derivatives
JP5985611B2 (ja) * 2011-05-03 2016-09-06 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途のための化合物
CA2853485A1 (en) * 2011-10-28 2013-05-02 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
JP6506313B2 (ja) * 2014-02-21 2019-04-24 フロスト バイオロジック，インコーポレーテッド 癌及び増殖性疾患の治療のための抗有糸分裂性アミド

Also Published As

Publication number Publication date
CN114634483B (zh) 2024-08-13
US20200397758A1 (en) 2020-12-24
RU2016135555A3 (es) 2018-10-05
IL247293B (en) 2021-01-31
CA2940237A1 (en) 2015-08-27
IL247293A0 (en) 2016-09-29
JP2017506267A (ja) 2017-03-02
ES2893374T3 (es) 2022-02-08
WO2015127284A2 (en) 2015-08-27
EP3107909B1 (en) 2021-07-14
US20220008395A1 (en) 2022-01-13
AU2015218775A1 (en) 2016-08-25
RU2713179C2 (ru) 2020-02-04
JP6506313B2 (ja) 2019-04-24
AU2015218775C1 (en) 2020-01-16
BR112016019161A2 (es) 2017-08-15
US12383533B2 (en) 2025-08-12
CA2940237C (en) 2023-03-07
US20180325871A1 (en) 2018-11-15
CN114634483A (zh) 2022-06-17
WO2015127284A3 (en) 2015-10-15
BR112016019161B1 (pt) 2022-12-20
SG11201606869TA (en) 2016-09-29
US11129813B2 (en) 2021-09-28
KR20160116009A (ko) 2016-10-06
ZA201606471B (en) 2025-06-25
KR102420508B1 (ko) 2022-07-13
EP3107909A2 (en) 2016-12-28
AU2015218775B2 (en) 2019-06-20
US10016398B2 (en) 2018-07-10
US10772872B2 (en) 2020-09-15
SG10202000590SA (en) 2020-03-30
CN106068263A (zh) 2016-11-02
RU2016135555A (ru) 2018-03-28
MX390530B (es) 2025-03-20
US20170172984A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CO2017006962A2 (es) Derivados de 2-anilinopirimidina sustituida como moudladores de egfr
IL254719A0 (en) Indoleamine 3,2-dioxygenase inhibitors for cancer treatment
TW201613872A (en) IRAK4 inhibiting agents
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
NZ726723A (en) Heteroaryl compounds for kinase inhibition
GEP20186933B (en) Substituted dihydroisoquinoline compounds
LT3139925T (lt) Valbenazino dozavimo režimas, skirtas gydyti hiperkinetinio judėjimo sutrikimus
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
MX2016010877A (es) Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX2016009663A (es) Derivados de icariina.
LT3210973T (lt) Heteroarilo junginiai, skirti akių ligų gydymui
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
JOP20190163B1 (ar) منشط nrf2
MX379401B (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
MX2019002607A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
ECSP17000222A (es) Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer
NZ763986A (en) Heteroaryl compounds for kinase inhibition